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CLINICAL RESEARCH
Heart Failure in Humans Reduces
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HIGHLIGHTS
 Contractile assays were performed using multicellular preparations isolated from the left and right ventricles of
organ donors and patients with heart failure.
 Heart failure reduced maximum force and power by approximately 30% in the myocardium from both ventricles.
 Heart failure increased the Ca2D sensitivity of contraction, but the effect was bigger in right ventricular tissue
than in left ventricular samples.
 The changes in Ca2D sensitivity may reflect ventricle-specific post-translational modifications to sarcomeric
proteins.
SUMMARY
This study measured how heart failure affects the contractile properties of the human myocardium from the
left and right ventricles. The data showed that maximum force and maximum power were reduced by
approximately 30% in multicellular preparations from both ventricles, possibly because of ventricular
remodeling (e.g., cellular disarray and/or excess fibrosis). Heart failure increased the calcium (Ca2þ) sensitivity
of contraction in both ventricles, but the effect was bigger in right ventricular samples. The changes in Ca2þ
sensitivity were associated with ventricle-specific changes in the phosphorylation of troponin I, which
indicated that adrenergic stimulation might induce different effects in the left and right ventricles.
(J Am Coll Cardiol Basic Trans Science 2020;5:786–98) © 2020 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
I n healthy humans, the left ventricle (LV) is athick-walled, bullet-shaped chamber that gener-ates approximately 120 mm Hg during systole.
Conversely, the right ventricle (RV) is a thinner
crescent-shaped structure that produces approxi-
mately 25 mm Hg (1,2). Laplace’s law (3) shows that
wall thickness will contribute to the systolic pressure
difference, but it is not known whether interventric-
ular differences in contractile function augment the
structural effect.
The impact of heart failure on cells from the LV
and RV is also unclear. Although numerous studies
have shown that heart failure reduces maximum
force and increases the calcium (Ca2þ) sensitivity of
contraction of the permeabilized LV myocardium
(410), few experiments have been performed using
human RV samples. One recent study by Hsu et al.
(11) demonstrated that the Ca2þ sensitivity of
contraction was increased in the RV of patients who
had systemic sclerosis-associated pulmonary arterial
hypertension. However, these investigators were not
able to study LV tissue. Previous experiments using
rat models of heart failure have yielded apparently
conflicting results. Belin et al. (12) demonstrated that
heart failure reduced maximum force in myocytes
from both ventricles. Conversely, Perreault et al. (13)
showed that heart failure increased maximum force
in RV tissue but had no effect on LV samples. Belin
et al. (12) found that heart failure reduced Ca2þ
sensitivity in the LV without affecting the RV,
whereas Perreault et al. (13) observed no change in
LV samples but did observe an increase in the
sensitivity of RV tissue.
This paper extends these studies to the human
myocardium. The data showed that heart failure
reduced the maximum force and power generated by
multicellular preparations from both ventricles
without changing contractile kinetics. Ca2þ sensi-
tivity was increased in failing myocardium from both
ventricles, but the effect was greater for RV samples
than that for LV tissue. Biochemical assays suggested
that the sensitivity effects might reflect ventricle-
specific modulation of the phosphorylation of car-
diac troponin I (TnI).
AB BR E V I A T I O N S
AND ACRONYM S
Ca2þ = calcium
Fpas = passive force
Fact = maximum Ca2D-
activated force
ktr = rate of force recovery
LV = left ventricle
MyBP-C = myosin binding
protein-C
nH = Hill coefficient
Pmax = maximum power output
PKA = protein kinase A
RLC = regulatory light chain
RV = right ventricle
TnI = troponin I
Vmax = maximum shortening
velocity
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ in-
stitutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit
the JACC: Basic to Translational Science author instructions page.
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METHODS
HUMAN SAMPLES. Myocardial samples were ac-
quired at the University of Kentucky using a pub-
lished protocol (14). Briefly, hearts from 12 patients
who underwent cardiac transplantation
(Supplemental Table S1) and from 5 organ donors who
did not have heart failure (Supplemental Table S2)
were handed to a researcher in the operating room,
who then dissected samples from through-wall sec-
tions of the distal region of the LV and RV. LV samples
were further dissected transmurally into sub-
epicardial, mid-myocardial, and sub-endocardial
specimens. RV samples were not separated trans-
murally because the RV wall is typically much
thinner. Specimens were snap frozen in liquid nitro-
gen within approximately 30 min and stored in the
vapor phase of liquid nitrogen until use. The Uni-
versity of Kentucky Institutional Review Board
approved all procedures, and subjects or their legally
authorized representatives gave informed consent.
Previous data from the laboratory (15) showed
that heart failure had a greater impact on the con-
tractile properties of the middle transmural region of
the LV than on samples from the sub-epicardium or
sub-endocardium. This study compared samples
from the RV and the LV mid-myocardium to
optimize the probability of detecting important
effects.
Table 1 summarizes clinical characteristics and the
use of medications for the patients and organ donors.
PREPARATIONS AND EXPERIMENTAL SETUP. Multi-
cellular preparations were obtained by mechanical
disruption of approximately 100 mg of tissue fol-
lowed by chemical permeabilization (1% v/v Triton
detergent). Preparations (860  248 mm) from 17 pa-
tients (5 nonfailing and 12 failing hearts) were
attached between a force transducer (resonant fre-
quency, 600 Hz; Model 403, Aurora Scientific, Aurora,
Ontario, Canada) and a motor (step time 0.6 ms;
model 312B, Aurora Scientific) and stretched to a
sarcomere length of 2.24  0.01 mm in pCa (¼
log10[Ca2+]) 9.0 solution. The cross-sectional area
(4.05  2.08  108 m2) was estimated from the width
of the preparation, assuming a circular profile. Mea-
surements were performed at 15 C using SLControl
software (16).
FORCE AND Ca2D SENSITIVITY MEASUREMENTS. As
described by Haynes et al. (15), preparations were
initially activated in a solution with a saturating Ca2þ
concentration of pCa 4.5. Maximum force was defined
as the steady-state force measured during this trial.
Subsequent trials measured force in solutions with
higher pCa values. Force values were corrected for
potential preparation-dependent run down using
reference contractions measured in pCa 9.0 and pCa
4.5 solutions throughout the protocol.
Tension pCa curves were calculated by fitting a
function of the form:
F ¼ Fpas þ Fact ½Ca
2þnH
½Ca2þnH þ Ca2þ50 nH (Eq. 1)
to the data, where Fpas is the passive force, Fact is
maximum Ca2þ-activated force, nH is the Hill coeffi-
cient, and is the free Ca2þ concentration needed to
develop half-maximum Ca2þ-dependent force.
Thirty-one of the 98 preparations studied were dis-
carded from the analysis because the force measured
in pCa 4.5 solution dropped by >30% during the
protocol (n ¼ 19), or the r2 value for the fit to the Hill
curve was <0.95 (n ¼ 12).
POWER MEASUREMENTS. Myocardial power output
was measured by allowing each preparation to
shorten against pre-set loads for 80 ms in pCa 4.5
solution. Shortening velocity was calculated as the
rate of change of fiber length during the final 50 ms of
each force clamp. A hyperbolic equation of the form
(Fþa) (Vþb) ¼ (Fmaxþa) b was then fitted to the
dataset, where F is force, Fmax is the isometric force,
and a and b are constants. Vmax, the preparation’s
maximum shortening velocity, was estimated by
extrapolating the equation to zero force.
TABLE 1 Summary of Clinical Characteristics and Medication Use for Patients
and Organ Donors
Heart Transplant Organ Donor p Value
Age (yrs) 48.0  17.3 41.7  15.7 0.494
Male 58.3 60.0 1.000
Ejection fraction (%) 24.3  10.8 47.6  15.6 0.006
Percentage of patients/donors taking medication
b-blocker 83.3 0.0 0.008
ACE inhibitor 83.3 0.0 0.008
Statin 66.7 25.0 0.262
Aldosterone antagonist 50.0 0.0 0.234
Inotrope 83.3 0.0 0.008
Digitalis 8.3 0.0 1.000
Vasopressor 0.0 50.0 0.050
Aspirin 75 25.0 0.118
Values are mean  SD or %. p Values for age and ejection fraction were calculated using unpaired
Student’s t-tests. All other p-values were calculated using Fisher’s exact tests. Data values that
were unknown for a patient or organ donor were excluded from the analysis.
ACE ¼ angiotensin-converting enzyme.
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Because power is the product of force and velocity,
power-force curves were calculated by fitting the
following function:
P ¼ F b

Fmax þ a
F þ a  1

(Eq. 2)
to the experimental data. Maximum power, Pmax, was
calculated as the greatest value of Equation 2. Data
from the 43 preparations, in which the r2 value for the
power-force fit was <0.9, were analyzed.
BIOCHEMICAL ASSAYS. The phosphorylation sta-
tuses of TnI, myosin binding protein-C (MyBP-C), and
myosin regulatory light chain (RLC) were analyzed
using gel electrophoresis as described by Haynes et al.
(15). The samples used in these gels were saved from
the homogenate after the mechanical disruption and
chemical permeabilization procedures were used to
prepare samples for contractile assays. Phosphory-
lated proteins were assessed using Pro-Q Diamond
(Invitrogen, Carlsbad, California). Total protein was
measured using SYPRO Ruby (Invitrogen). Data from
multiple gels were collated and normalized to values
from a single reference control that was included in
every experiment.
TnI Ser23/24 specific phosphorylation was deter-
mined by Western blot as described by Nixon et al.
(17) and Salhi et al. (18) using the following anti-
bodies: rabbit anti-phosphorylated TnI Ser-23/24 (Cell
Signaling Technology, Inc., Danvers, Massachusetts),
anti-rabbit Cy5-labeled secondary antibody (Jackson
ImmunoResearch Laboratories, Inc, West Grove,
Pennsylvania), mouse anti-cardiacT TnI antibody
(clone 5; Fitzgerald, Acton, Massachusetts), and anti-
mouse Cy2 labeled fluorescent secondary antibody
(Jackson ImmunoResearch Laboratories).
STATISTICAL ANALYSIS. Data were analyzed in SAS
version 9.4 (SAS Institute, Inc., Cary, North Carolina)
using linear mixed effects models that incorporated 2
main effects (heart failure status and ventricular re-
gion) and their interaction. Testing for the interaction
determined whether the effect of 1 independent var-
iable depended on the other. An example of an
interaction is a value that decreases with heart failure
in samples from the LV but increases with heart fail-
ure in samples from the RV, so that the effect of heart
failure depends on the ventricle that is being studied.
As previously described (15), the linear mixed
model accounted for the hierarchical nested structure
of the data (values obtained from multiple prepara-
tions from different regions of the same hearts) and
had greater statistical power than a standard 2-way
analysis of variance test for this type of experimental
design. Post hoc analyses were performed using
Tukey-Kramer corrections that took into account the
number of hearts and the number of samples from
each heart. The p values <0.05 were considered sig-
nificant. Data are reported as mean  SEM, unless
otherwise specified. Data could be clinically signifi-
cant although statistical significance was not ach-
ieved, especially with smaller sample sizes.
RESULTS
HEART FAILURE REDUCES Ca2D-ACTIVATED FORCE
IN MULTICELLULAR PREPARATIONS FROM BOTH
VENTRICLES. Figure 1 and Supplemental Figure 1
show force normalized to the cross-sectional area as
a function of the activating Ca2þ concentration (pCa)
for multicellular preparations from the LVs and RVs
of organ donors and patients with heart failure. The
solid lines are the best-fits of Equation 1 to the mean
data values measured at each Ca2þ concentration for
each type of preparation.
Figure 2 shows passive forces (Fpas) and Ca2þ-acti-
vated forces (Fact) calculated by fitting Equation 1 to
the data for each experimental preparation. The sta-
tistical analysis showed that Fpas did not depend on
heart failure status or ventricular region. In contrast,
Fact was reduced by >30% in samples from failing
hearts (p < 0.001). Similar reductions were observed
in the samples from the LVs and RVs (i.e., there was
no effect of cardiac region).
HEART FAILURE HAS A GREATER EFFECT ON THE
Ca2D SENSITIVITY OF THE RV. Figure 3 shows the
Ca2þ sensitivity (pCa50) and the cooperativity (nH)
calculated for each multicellular preparation. The
pCa50 values were higher for the failing samples than
that for preparations from the organ donors
(p ¼ 0.005) but there was a statistical interaction
between disease status and cardiac region
(p ¼ 0.029). The interaction meant that the increase
in calcium sensitivity induced by heart failure was
statistically greater in samples from the RV than in
samples from the LV. In addition, the post hoc tests
showed that in failing hearts, samples from the RV
were more sensitive to Ca2þ than the samples from
the LV (p ¼ 0.039). No statistically significant effects
were observed for the nH values.
HEART FAILURE REDUCES THE POWER OUTPUT OF
MYOCARDIUM FROM BOTH VENTRICLES. Power
quantified the rate at which the myocardial prepara-
tions performed mechanical work and was calculated
as the product of force and velocity. Figure 4A to 4C
illustrates the experimental technique that was used
to calculate the maximum shortening velocity (Vmax)
and the maximum power output (Pmax) of a single
representative preparation. Data from multiple
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preparations are shown in Figure 4D and 4E. As in the
case of Fact (Figure 2B), Pmax was reduced by approx-
imately 30% in samples from both the LVs and RVs of
failing hearts. In contrast, no statistically significant
effects were observed for Vmax.
Vmax is believed to depend on cross bridge cycling
kinetics (19), which can be estimated by measuring
the rate of force recovery (ktr) after a quick shortening
and/or re-stretch perturbation. Figure 5A shows
representative records measured for a LV preparation
isolated from an organ donor. Consistent with previ-
ous results from human myocardium (15), force
overshot the steady-state isometric value during the
recovery phase (20,21). The ktr values increased
approximately linearly with steady-state isometric
force in every experimental group (Figure 5B). The
rates measured in maximally activating pCa 4.5 so-
lution did not depend on heart failure status or ven-
tricular region.
Data for ktr values measured at sub-maximal acti-
vation levels ranging from pCa 6.0 to pCa 5.2 are
shown in Supplemental Figure S2. The kinetics were
faster in the samples from patients with heart failure
at some activation levels, with the difference being
more pronounced in the RV. The physiological sig-
nificance of these results is not yet clear.
HEART FAILURE MODULATES THE PHOSPHORYLA-
TION OF MYOFILAMENT PROTEINS. Figure 6A shows
images from a representative gel that that was stained
with Pro-Q Diamond to show phosphorylated proteins
and then SYPRO Ruby to show total protein. Figure 6B
to 6D shows data obtained from similar images
quantifying the phosphorylation levels of TnI, MyBP-
C, and RLC. Both TnI and RLC exhibited a statistical
interaction (p ¼ 0.037) between heart failure status
and the cardiac region with the phosphorylation
levels trending higher in RV samples from organ do-
nors and lower in RV samples from patients with
heart failure.
The data for MyBP-C showed a different pattern.
No interaction was observed, but there was a main
effect of heart failure status (p ¼ 0.010). This implied
that the phosphorylation of MyBP-C was lower in
samples from both ventricles in failing hearts.
Supplemental Figures S3 to S7 show the relative
phosphorylation of TnI, MyBP-C, and RLC plotted
against pCa50, nH, Fpas, Fact, and the maximum
value of ktr. Deming regression (which takes into
account experimental uncertainty in both the x and y
coordinates) showed that pCa50 was negatively
correlated with the relative phosphorylation of both
MyBP-C and RLC, and that Fact was positively
correlated with the relative phosphorylation of
MyBP-C.
Pro-Q Diamond is commonly used to study sar-
comeric proteins (2224) but the stain is not
completely specific to phosphorylated proteins and
FIGURE 1 Force Pca Curves
Force
normalized
to
area
(kN m-2)
0
30
pCa
9.0 6.5 5.5 4.5
Organ donor
Region pCa50 nH
LV 5.62 ± 0.05 2.61 ± 0.32
RV 5.53 ± 0.03 2.29 ± 0.35
A
Force
normalized
to
area
(kN m-2)
0
30
pCa
9.0 6.5 5.5 4.5
Heart failure
Region pCa50 nH
LV 5.67 ± 0.01 2.87 ± 0.17
RV 5.73 ± 0.02 2.84 ± 0.13
B
Data for multicellular preparations isolated from the left ventricle (LV) and right ventricle (RV) of (A) organ donors and (B) patients who had
heart failure. Symbols and table entries show mean  SEM. Data were acquired as follows: LV organ donor, 9 preparations from 4 hearts; RV
organ donor, 12 preparations from 5 hearts; LV heart failure, 22 preparations from 10 hearts; RV heart failure, 24 preparations from 11 hearts.
pCa ¼ log10[Ca2þ]. nH ¼ Hill coefficient.
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does not provide information about post-
translational modifications to identified residues.
Western blotting (Figure 7) was performed to address
these potential limitations. As for the experiments
performed using Pro-Q Diamond (Figure 6B), the
phosphorylation status of TnI 23/24 exhibited a sta-
tistical interaction (p ¼ 0.039) between heart failure
status and cardiac region, which indicated that the
FIGURE 2 Heart Failure Reduces Ca2þ-Activated Force in Multicellular Preparations From Both Ventricles
Fpas
(kN m-2)
0.0
8.0
Disease status, p = 0.399
Cardiac region, p = 0.856
Disease status*Cardiac region, p = 0.408
LV RV
Organ
donor
LV RV
Heart
failure
A
Fact
(kN m-2)
0.0
40.0
Disease status, p < 0.001
Cardiac region, p = 0.733
Disease status*Cardiac region, p = 0.101
LV RV
Organ
donor
LV RV
Heart
failure
p = 0.002
p < 0.001
B
(A) Passive (Fpas) and (B) active (Fact) force values deduced by fitting Equation 1 to data from the individual preparations summarized in
Figure 1. The total force in pCa 4.5 solution (F) is equal to FpasþFact. the mean r2 value for these fits was 0.979  0.002. in this, and all
similar Figures, data were analyzed using a linear mixed model that tested for 2 main effects (heart failure status and ventricular region) and
their statistical interaction. Post hoc tests were performed using Tukey-Kramer corrections that took into account the number of hearts as
well as the number of samples From each heart. Ca2þ ¼ calcium; other abbreviations as in Figure 1.
FIGURE 3 Heart Failure Has a Greater Effect on the Ca2þ Sensitivity of Myocardium From the RV
pCa50
5.3
5.9
Disease status, p = 0.005
Cardiac region, p = 0.919
Disease status*Cardiac region, p = 0.029
LV RV
Organ
donor
LV RV
Heart
failure
p = 0.039
p < 0.001
A
nH
0.0
6.0
Disease status, p = 0.158
Cardiac region, p = 0.630
Disease status*Cardiac region, p = 0.581
LV RV
Organ
donor
LV RV
Heart
failure
B
Values of (A) Ca2þsensitivity (pCa50) and (B) cooperativity (nH) deduced by fitting Equation 1 to data from the individual preparations
summarized in Figure 1. Abbreviations as in Figure 1.
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effect of heart failure on TnI phosphorylation de-
pends on the ventricle.
DISCUSSION
To our knowledge, this is the first study that sys-
tematically investigated how heart failure in
humans affects the contractile properties of chem-
ically permeabilized myocardial samples from LVs
and RVs. The main findings are that heart failure: 1)
reduces isometric force and maximum power
output in preparations from both ventricles; and 2)
increases the calcium sensitivity (pCa50) of RV tis-
sue more than that of LV tissue. Biochemical data
suggested that the changes in calcium sensitivity
might reflect ventricle-specific modulation of TnI
phosphorylation.
REDUCED ISOMETRIC FORCE AND POWER IN
FAILING TISSUE MAY REFLECT VENTRICULAR
REMODELING. Figures 1 and 2B show that heart fail-
ure reduced maximum Ca2þ-activated force by at
least 30% in multicellular preparations from both
ventricles. Maximum power was also reduced by a
similar amount in both ventricles (Figure 4D). In
principle, these effects could reflect a change in the
fractional volume occupied by sarcomeres and/or al-
terations to cross-bridge kinetics that reduce the
force-generating capacity of myosin heads in
failing ventricles.
FIGURE 4 Heart Failure Reduces the Maximum Power Output of Multicellular Preparations From Both Ventricles
Force
normalized
to
area
(kN m-2)
0
20
Organ donor - LVA
Shortening
velocity
(muscle
lengths s-1)
0.0
0.7
Organ donor - LVB
Muscle
length
(µm)
870
1100
Time (s)
0.00 0.05 0.10 0.15
Power
(W kg-1)
0.0
0.8
Force normalized to
area (kN m-2)
Vmax
(muscle
lengths s-1)
0.0
2.0
LV RV
Organ
donor
LV RV
Heart
failure
Disease status, p = 0.183
Cardiac region, p = 0.080
Disease status*Cardiac region, p = 0.484
C
Pmax
(W kg-1)
0.0
0 20
1.1
LV RV
Organ
donor
LV RV
Heart
failure
Disease status, p = 0.031
Cardiac region, p = 0.600
Disease status*Cardiac region, p = 0.939
p = 0.028
D
(A) Representative traces showing (top) force and (bottom) length for a multicellular preparation released to shorten against different loads.
(B) Velocity and power plotted against force for these records. (C) Maximum shortening velocity and (D) maximum power for preparations
from both ventricles. Data were acquired as follows: LV organ donor, 5 preparations from 3 hearts; RV organ donor, 12 preparations from 5
hearts; LV heart failure, 10 preparations from 7 hearts; RV heart failure, 16 preparations from 8 hearts. Pmax ¼ maximum power output;
Vmax ¼ maximum shortening velocity; other abbreviations as in Figure 1.
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Figures 4E, 5B, and 5C show that neither Vmax nor
ktr were affected by heart failure status or cardiac
region at maximal levels of Ca2þ activation. Both pa-
rameters are indicative of cross-bridge kinetics and
would be expected to change if the attachment and/or
detachment rates of myosin were altered. Thus, the
present data did not support a kinetic basis for the
reduction in force. Instead, the mostly likely expla-
nation for the approximate 30% reduction in force
and power in failing samples was a decrease
in the fractional volume occupied by contractile
machinery.
This conclusion was consistent with a previous
study by Haynes et al. (15) that compared the con-
tractile properties of multicellular preparations from
the sub-endocardial, mid-myocardial, and sub-
epicardial regions of the LV free wall of organ do-
nors and patients with heart failure. Histological data
(staining with picrosirius red) included in that study
showed that the collagen to tissue ratio fell from
approximately 27% in mid-myocardial tissue from
patients with heart failure to approximately 15% in
corresponding samples from organ donors. Unfortu-
nately, histological data from RV samples were not
available for the present study. However, if the
preparations had exhibited similar trends to those
reported by Haynes et al., the increased fibrosis in the
failing samples could account for approximately 50%
of the reductions shown in Figures 1, 2B, and 4E. Other
potential mechanisms that could reduce maximum
contractile force in failing myocardium include
disarray of myocytes and/or myofibrils (25) and
changes in the fractional volume occupied by mito-
chondria (26). These possibilities could be tested in
future work: 1) measuring the contractile function of
single myocytes that do not have extracellular
FIGURE 5 Rates of Tension Recovery Do Not Depend on Heart Failure Status or Ventricular Region at Maximum Levels of
Ca2þ Activation
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(A) Representative traces showing (top) force normalized to cross-sectional area and (bottom) length for a preparation subjected to a rapid
shortening/re-stretch protocol (20% muscle length, 20 ms hold). Note the large overshoots that are characteristic of force recovery in
human myocardium. The rate of force recovery (ktr) was calculated by fitting a single exponential to the trace between the minimum force
after re-stretch and the maximum force attained during the recovery. (B) ktr values plotted against isometric force. Symbols show mean 
SEM for trials in different pCa solutions. Data were acquired from the same preparations summarized in Figure 1. (C) Statistical analysis of ktr
values measured in pCa 4.5 solution. Abbreviations as in Figure 1.
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collagen (27); and 2) analyzing tissue samples with
immunohistochemistry and electron microscopy (28).
INTERVENTRICULAR DIFFERENCES IN Ca2D
SENSITIVITY ARE ASSOCIATED WITH PHOSPHORY-
LATION OF TnI. Because myocardium is only
transiently activated during each heart beat, its
sensitivity to Ca2þ (quantified as a pCa50 value) is
critically important for function. For example, all
other things being equal, myocytes with higher pCa50
values will develop more contractile force in response
FIGURE 6 Heart Failure Modulates the Phosphorylation of Myofilament Proteins
A
TnI
Pro-Q to
SYPRO
(Aribitrary
units)
0.0
4.2
LV RV
Organ
donor
LV RV
Heart
failure
Condition, p = 0.102
Region, p = 0.504
Condition*Region, p = 0.037
p = 0.019
B
MyBP-C
Pro-Q to
SYPRO
(Aribitrary
units)
0.0
2.5
LV RV
Organ
donor
LV RV
Heart
failure
Condition, p = 0.010
Region, p = 0.244
Condition*Region, p = 0.725
p = 0.020
p = 0.010
C
RLC
Pro-Q to
SYPRO
(Aribitrary
units)
0.0
3.0
LV RV
Organ
donor
LV RV
Heart
failure
Condition, p = 0.829
Region, p = 0.477
Condition*Region, p = 0.021
p = 0.035
D
(A) Representative images from a gel stained with Pro-Q Diamond (to show phosphorylated proteins) and then SYPRO Ruby (to show total
protein). Statistical analyses for (B) troponin I (TnI), (C) myosin binding protein-C (MyBP-C), and (D) regulatory light chain (RLC). Data were
acquired as follows: LV organ donor, 8 samples from 4 hearts; RV organ donor, 8 samples from 4 hearts; LV heart failure, 10 samples from 9
hearts; RV heart failure, 8 samples from 8 hearts.
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to a given intracellular Ca2þ transient than myocytes
with low Ca2þ sensitivities. Figure 3A confirmed pre-
vious work (7,29) that showed that myocardium from
failing hearts is more sensitive to Ca2þ than tissue
from organ donors (p < 0.005). One possibility is that
the failing heart enhances Ca2þ sensitivity to try and
compensate for its reduced force-generating capacity.
Supplemental Figure S1 superposes force pCa curves
measured with samples from organ donors and pa-
tients with heart failure. The curves nearly overlap at
the sub-maximal activation levels where the heart
normally operates.
The present data also revealed a new statistical
interaction between heart failure status and cardiac
ventricles. More specifically, heart failure increased
the Ca2þ sensitivity of RV myocardium more than that
of LV tissue. Figures 6 and 7 show data that provide
insights into the molecular mechanisms that drive
these effects. Two independent measures of TnI
phosphorylation (Pro-Q Diamond staining [Figure 6B]
and Western blotting with an antibody specific to Ser-
23/24 phosphorylation [Figure 7B]) showed a statisti-
cal interaction between disease status and the cardiac
ventricle. It is well known that phosphorylation of
TnI (most notably at serine 23/24) reduces Ca2þ
sensitivity (4,6,10,30–35)); therefore, these statistical
interactions are consistent with post-translational
modifications to TnI contributing to the ventricle-
specific effects.
Phosphorylation of RLC also exhibited a signifi-
cant interaction (Figure 6C) with higher phosphor-
ylation levels again being associated with reduced
Ca2þ sensitivity. This effect is also evident in
Supplemental Figure S3C, which shows the relative
phosphorylation of RLC plotted against pCa50. This
was a more complex relationship because increased
phosphorylation of RLC was shown to enhance Ca2þ
sensitivity (36,37). One possibility was that the
phosphorylation of RLC changes during human
heart failure partially compensated for the post-
translational modifications to TnI and mitigated
diastolic dysfunction. A similar conclusion was
FIGURE 7 Tn1 Phosphorylation Exhibits a Statistical Interaction Between Heart Failure Status and Ventricular Region
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(A) Western blots probed with antibodies for total TnI (top) and (bottom) TnI phosphorylated at serine 23/24. (B) Data showing phos-
phorylated TnI to total TnI. Data were acquired as follows: LV organ donor, 4 samples from 4 hearts; RV organ donor, 4 samples from 4
hearts; LV heart failure, 8 samples from 8 hearts; RV heart failure, 8 samples from 8 hearts. Abbreviations as in Figures 1 and 6.
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reached by van der Velden et al. (5), who observed
changes in the phosphorylation of TnI and RLC in
human heart failure that were similar to those
shown here.
Figure 6D shows that MyBP-C was dephosphory-
lated in failing samples from both ventricles. This
modification increased myofilament Ca2þ sensitivity
(38–41) and could therefore be driving the global in-
crease in Ca2þ sensitivity observed in the failing
samples (Figure 3A and Supplemental Figure S3B).
The physiological basis of the interventricular dif-
ference in Ca2þ-sensitivity remains unclear. One
possibility is that the ventricles are tuned to different
mechanical loads. Another possibility is that they
respond differently to b-adrenergic stimulation.
Recent work that used Förster Resonance Energy
Transfer (FRET) biosensors suggested that maximal
inotropy required compartmentalized signaling re-
sponses (42). In addition, Surdo et al. (43) reported an
enrichment in the expression of genes involved in
adrenergic signaling in calls from the RV of healthy
human donors in comparison to cells from the LV
using single cell RNA-Seq. Building on this theme,
Molina et al. (44) showed that in healthy dogs, the RV
was more sensitive to b-adrenergic stimulation and
exhibited increased activity of protein kinase A (PKA).
This enzyme phosphorylates TnI (45) so differential
responses to b-adrenergic stimulation could
contribute to the effects shown in Figures 6B and 7B.
Interestingly, Hsu et al. (11) showed that treatment
with PKA equalized the Ca2þ sensitivity of RV
myocardium from organ donors and in patients with
systemic sclerosis-associated pulmonary hyperten-
sion, a finding that further reinforced the importance
of PKA signaling in disease. However, the present
data suggested that PKA was unlikely to be the only
mechanism that contributed to interventricular dif-
ferences because enhanced activity of the kinase in
the RV should also have increased the phosphoryla-
tion of MyBP-C. This was not observed (Figure 6C).
STUDY LIMITATIONS. Although experiments using
human biospecimens sometimes have greater trans-
lational significance than studies that only use ani-
mals, they also have limitations. For example, it was
exceedingly difficult to control for all of the potential
confounders (including age, sex, genetic background,
and comorbidities) that could have influenced the
data (46). Some clinical data were also unavailable.
This reduced the statistical power of tests that
investigated potential relationships between cellular
and organ-level function and was a particular
concern for parameters related to the RV
(Supplemental Table S3).
Sample processing was another concern. All of the
hearts used were procured by the same personnel and
cooled in ice cold saline within moments of being
removed from the patient or donor (14). Nevertheless,
the mean time from procurement to the sample being
frozen in liquid nitrogen was approximately 30 min.
As demonstrated by Walker et al. (47), this is clearly
enough time to alter the post-translational status of
sarcomeric proteins, which sometimes changes on a
beat-to-beat basis (48).
Another issue was that that the patients and organ
donors were treated with drugs that were intended to
alter contractile properties. Catecholamine levels also
rose during tissue procurement (46), which might
have added additional complications. Again, it was
difficult to know how to overcome these limitations
in a translational research setting without having a
negative impact on patient care.
Finally, although this study investigated the
phosphorylation of several key myofilament proteins,
the experiments could have missed other critical
modifications. This could be addressed in
future work using an unbiased approach (e.g.,
phosphoproteomics).
CONCLUSIONS
This study presented 3 important results. First, heart
failure in humans depressed maximum contractile
force and maximum power by similar amounts in
myocardium from both ventricles. Second, human
heart failure increased the Ca2þ sensitivity of RV
myocardium more than the Ca2þ sensitivity of LV
myocardium. Third, the differences in Ca2þ sensi-
tivity were likely to involve interventricular differ-
ences in post-translational modifications to
sarcomeric proteins, including TnI.
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